🔴 Cerenome is trading 5.7% down in pre-market — no clear company-specific catalyst found

Cerenome is trading at $1.82, with a -5.74% move in pre-market; no clear company-specific news was found to explain the decline.

• Cerenome’s molecular profile tests became available to order on October 12. The launch was announced October 6 and does not establish a reason for the drop.
• The Florida Blue coverage agreement was announced October 8 and accompanied the prior session’s rise, not the current downward move.
• Healthcare sector strength is positive context but does not explain the stock’s decline.